Table 1 Final diagnosis of studied pulmonary nodules according to our standard of reference
From: The role of dynamic contrast-enhanced CT in characterization of solitary solid pulmonary nodules
Pathology | The study group (n = 40) |
|---|---|
Benign nodules | |
TB | 2 (5.0%) |
Septic pulmonary embolism | 1 (2.5%) |
Non-specific inflammatory nodule | 2 (5.0%) |
Wagner granulomatosis | 1 (2.5%) |
AML with fungal infection | 1 (2.5%) |
Hamartoma | 1 (2.5%) |
Malignant nodules | |
Bronchogenic carcinoma | 5 (12.5%) |
Adenocarcinoma | 11 (27.5%) |
Primary | 5 (12.5%) |
Secondary | 6 (15%) |
Small cell lung cancer | 3 (7.5%) |
Large cell lung cancer | 2 (5.0%) |
Multiple myloma with pulmonary mets | 1 (2.5%) |
Ovarian cancer with pulmonary mets | 2 (5.0%) |
Nephrogenic tumor with pulmonary mets | 2 (5.0%) |
NHL with pulmonary mets | 2 (5.0%) |
Infiltrating duct carcinoma with pulmonary mets | 2 (5.0%) |
High grade sarcoma (leiomyosarcoma) with pulmonary mets | 1 (2.5%) |
Synovial sarcoma (liposarcoma) with pulmonary mets | 1 (2.5%) |